As of 2025-11-07, the Relative Valuation of Protagonist Therapeutics Inc (PTGX) is 23.56 USD. This relative valuation is based on P/E multiples. With the latest stock price at 79.78 USD, the upside of Protagonist Therapeutics Inc based on Relative Valuation is -70.5%.
The range of the Relative Valuation is 14.61 - 36.79 USD.
| Range | Selected | |
| Trailing P/E multiples | 17.5x - 23.6x | 20.6x |
| Forward P/E multiples | 19.1x - 30.4x | 24.8x |
| Fair Price | 14.61 - 36.79 | 23.56 |
| Upside | -81.7% - -53.9% | -70.5% |
| Date | P/E |
| 2025-11-05 | 93.10 |
| 2025-11-04 | 91.45 |
| 2025-11-03 | 90.80 |
| 2025-10-31 | 93.99 |
| 2025-10-30 | 93.07 |
| 2025-10-29 | 91.68 |
| 2025-10-28 | 93.86 |
| 2025-10-27 | 89.96 |
| 2025-10-24 | 89.49 |
| 2025-10-23 | 88.45 |
| 2025-10-22 | 87.87 |
| 2025-10-21 | 89.66 |
| 2025-10-20 | 91.72 |
| 2025-10-17 | 92.65 |
| 2025-10-16 | 90.53 |
| 2025-10-15 | 92.86 |
| 2025-10-14 | 91.98 |
| 2025-10-13 | 94.65 |
| 2025-10-10 | 104.01 |
| 2025-10-09 | 80.14 |
| 2025-10-08 | 78.06 |
| 2025-10-07 | 78.27 |
| 2025-10-06 | 76.68 |
| 2025-10-03 | 77.50 |
| 2025-10-02 | 77.68 |
| 2025-10-01 | 76.51 |
| 2025-09-30 | 79.42 |
| 2025-09-29 | 77.87 |
| 2025-09-26 | 80.60 |
| 2025-09-25 | 77.35 |
| 2025-09-24 | 78.84 |
| 2025-09-23 | 77.78 |
| 2025-09-22 | 77.12 |
| 2025-09-19 | 74.36 |
| 2025-09-18 | 74.29 |
| 2025-09-17 | 70.80 |
| 2025-09-16 | 70.04 |
| 2025-09-15 | 69.79 |
| 2025-09-12 | 70.37 |
| 2025-09-11 | 71.35 |
| 2025-09-10 | 69.03 |
| 2025-09-09 | 69.77 |
| 2025-09-08 | 67.17 |
| 2025-09-05 | 72.36 |
| 2025-09-04 | 71.25 |
| 2025-09-03 | 69.47 |
| 2025-09-02 | 70.35 |
| 2025-08-29 | 70.59 |
| 2025-08-28 | 69.50 |
| 2025-08-27 | 73.44 |